TEL AVIV, ISRAEL, July 10, 2006 – Compugen Ltd. (NASDAQ: CGEN) announced today that Martin Gerstel, Chairman of the Board, is scheduled to present at the 2006 C.E. Unterberg, Towbin Emerging Growth Opportunities Conference at 3:36 PM (Eastern Time) on Wednesday, July 12, 2006 at the Mandarin Oriental Hotel in New York City.
A live Webcast of the presentation will be available on the Compugen Website at http://www.wsw.com/webcast/ceut4/cgen/, and a replay will be available for 90 days following the presentation.
Compugen is a biotech company focused on drug and biomarker discovery. The Company’s powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company’s decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into traditional biology, chemistry and medicine. To date, Compugen’s discovery efforts have focused mainly on cancer, cardiovascular and immune-related diseases. Product development is pursued both in-house and through collaborative arrangements. The Company’s primary commercialization pathway is the out-licensing of validated therapeutic and diagnostic product candidates to leading companies under co-development and/or milestone and revenue sharing agreements. Compugen has established an agricultural biotechnology affiliate – Evogene, and a small-molecule drug discovery affiliate – Keddem Bioscience. For additional information, please visit Compugen’s corporate Website at www.cgen.com.